A Phase I Dose Escalation Study Evaluating the Safety and Biologically Active Dose of TM-601 Based on Perfusion MRI Imaging Criteria in Patients With Progressive and/or Recurrent Malignant Glioma.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Sep 2015
At a glance
- Drugs TM 601 (Primary)
- Indications Glioma
- Focus Adverse reactions
- 22 Jul 2009 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Jun 2009 Interim results presented at ASCO 2009, according to TransMolecular media release.
- 07 Apr 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.